Immunity Cells in Blood (Innate Immunity Signal Transduction in Human Leukocytes) | National Institute of Environmental Health S
Source: https://www.niehs.nih.gov/research/atniehs/labs/crb/studies/closed-studies/immunity
Archived: 2026-04-23 17:36
Immunity Cells in Blood (Innate Immunity Signal Transduction in Human Leukocytes) | National Institute of Environmental Health Sciences
Skip Navigation
Immunity Cells in Blood (Innate Immunity Signal Transduction in Human Leukocytes)
Close the left navigation
Add
Study Background
This study is no longer accepting participants.
To find studies that are currently recruiting, please visit the
Join an
NIEHS Study
website
For More Information
ClinicalTrials.gov
NIH Clinical Studies
The Innate Immunity Signal Transduction in Human Leukocytes is a research study to determine the response of immune cells from the bloodstream.
This study will investigate the response of immune cells to various signals in the test tube to determine how they sense the signals in the body and what substances they produce in response to them. It will determine how the cells may, under certain circumstances, contribute to inflammation, and will measure substances in the blood plasma (the liquid, non-cellular part of the blood) that might stimulate white blood cells, in order to understand how the blood responds to possible disease-related conditions.
Eligibility Criteria
Healthy men and non-pregnant women aged 18-65
Weighing at least 110 pounds
Normal, healthy adult donors as judged by screening questionnaire
Nonpregnant
HIV negative (proof required every 6 months we will conduct test)
Hepatitis B surface antigen and hepatitis C serology negative (checked every 6 months we will conduct test)
The rationale for HIV and hepatitis viral testing is that chronic viral infection may alter and possibly invalidate our experimental results. HIV and hepatitis results will be confidentially obtained. Testing will be contracted to an external certified laboratory and will be paid for by the study group. Results will be available only to the study doctor/PI (Fessler), the study coordinator, the CRU Director (Garantziotis, LAI), and the donor, with the few caveats that follow
Principal Investigator
Michael B. Fessler, M.D.
Chief, Clinical Research Branch;
Clinical Director and Chair - Clinical Advisory Committee (CAC);
Principal Investigator
Tel 984-287-4081
[email protected]
Stavros Garantziotis, M.D.
Tenure Track Investigator; Immunity, Inflammation, and Disease Laboratory
Tel 984-287-4412
Fax 919-541-9854
[email protected]
Back
to Top
Last Reviewed: December 30, 2025
Skip Navigation
Immunity Cells in Blood (Innate Immunity Signal Transduction in Human Leukocytes)
Close the left navigation
Add
Study Background
This study is no longer accepting participants.
To find studies that are currently recruiting, please visit the
Join an
NIEHS Study
website
For More Information
ClinicalTrials.gov
NIH Clinical Studies
The Innate Immunity Signal Transduction in Human Leukocytes is a research study to determine the response of immune cells from the bloodstream.
This study will investigate the response of immune cells to various signals in the test tube to determine how they sense the signals in the body and what substances they produce in response to them. It will determine how the cells may, under certain circumstances, contribute to inflammation, and will measure substances in the blood plasma (the liquid, non-cellular part of the blood) that might stimulate white blood cells, in order to understand how the blood responds to possible disease-related conditions.
Eligibility Criteria
Healthy men and non-pregnant women aged 18-65
Weighing at least 110 pounds
Normal, healthy adult donors as judged by screening questionnaire
Nonpregnant
HIV negative (proof required every 6 months we will conduct test)
Hepatitis B surface antigen and hepatitis C serology negative (checked every 6 months we will conduct test)
The rationale for HIV and hepatitis viral testing is that chronic viral infection may alter and possibly invalidate our experimental results. HIV and hepatitis results will be confidentially obtained. Testing will be contracted to an external certified laboratory and will be paid for by the study group. Results will be available only to the study doctor/PI (Fessler), the study coordinator, the CRU Director (Garantziotis, LAI), and the donor, with the few caveats that follow
Principal Investigator
Michael B. Fessler, M.D.
Chief, Clinical Research Branch;
Clinical Director and Chair - Clinical Advisory Committee (CAC);
Principal Investigator
Tel 984-287-4081
[email protected]
Stavros Garantziotis, M.D.
Tenure Track Investigator; Immunity, Inflammation, and Disease Laboratory
Tel 984-287-4412
Fax 919-541-9854
[email protected]
Back
to Top
Last Reviewed: December 30, 2025